Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
|Slideshows|August 23, 2018
Psychiatry Rounds: Workplace Mental Health and More
Author(s)Laurie Martin
The perils of job insecurity; depression and cardiac risks; the longest-running mental health study; smart drugs that aren’t so smart; heatstroke in psychiatric patients; an autism puzzler; and psychosis and eating disorders.
Advertisement
Advertisement
Related to this article
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The First Ever Treatment-Resistant Depression Awareness Day
2
What Makes Us Human? The Role of Psychiatry and the Future DSM
3
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
4
How Best to Manage Treatment-Resistant Depression
5